E7974

DRUG3 trials

Sponsors

Eisai Inc.

Conditions

Cancer, Malignant TumorsSolid Tumor Malignancies, Cancer

Phase 1

An Open-Label Study of E7974 Administered on Days 1, 8, and 15 of a 28-Day Cycle and Days 1 and 8 of a 21-Day Cycle in Patients With Solid Malignancies

CompletedNCT00121732

Eisai Inc.Solid Tumor Malignancies, Cancer

Start: 2005-07-31End: 2009-10-31Updated: 2015-07-01

A Phase 1 Open-Label Study of E7974 Administered on Days 1 and 15 of a 28-Day Cycle in Patients With Solid Malignancies

CompletedNCT00130169

Eisai Inc.Cancer, Malignant Tumors

Start: 2006-01-31End: 2009-08-31Updated: 2015-07-01

A Phase I Open Label Study of E7974 Administered on a Day 1 of 21-Day Cycle In Patients With Advanced Solid Tumors

CompletedNCT00165802

Eisai Inc.Cancer, Malignant Tumors

Start: 2006-05-31End: 2009-01-31Target: 40Updated: 2013-05-22